Background The biologic disease‐modifying anti‐rheumatic drugs (DMARDs) are very
effective in treating rheumatoid arthritis (RA), however there is a lack of head‐to‐head …

Background Methotrexate is a folic acid antagonist widely used for the treatment of neoplastic
disorders. Methotrexate inhibits the synthesis of deoxyribonucleic acid (DNA), ribonucleic …

Objective. To compare the benefit and safety of tocilizumab to placebo in patients with
rheumatoid arthritis (RA). Methods. We searched multiple databases for published randomized or …

Background: We sought to compare the benefits and safety of 6 biologics (abatacept,
adalimumab, anakinra, etanercept, infliximab and rituximab) in patients with rheumatoid arthritis. …

Background Rituximab is a selective, B‐cell depleting, biologic agent for treating refractory
rheumatoid arthritis (RA). It is a chimeric monoclonal antibody targeted against CD 20 that is …

Background Tocilizumab, a new biologic that inhibits interleukin‐6, is approved for treatment
of rheumatoid arthritis (RA) in Europe, Japan and the US. Objectives To assess the efficacy …

Background Infliximab is a human murine chimeric anti‐tumour necrosis factor alpha monoclonal
antibody recently approved for the treatment of refractory RA. Objectives To assess the …

Background Etanercept is a soluble tumour necrosis factor alpha‐receptor disease‐modifying
anti‐rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Objectives …

Background Biologic disease‐modifying anti‐rheumatic drugs (DMARDs: referred to as
biologics) are effective in treating rheumatoid arthritis (RA), however there are few head‐to‐head …

Background Gout is the most common inflammatory arthritis in men over 40 years and has
an increasing prevalence among postmenopausal women. Lowering serum uric acid levels …